Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

October 14, 2024

Study Completion Date

December 11, 2024

Conditions
Cystic FibrosisPneumonia, Bacterial
Interventions
DRUG

Imipenem/Cilastatin/Relebactam

Patients will receive intravenous imipenem/cilastatin/relebactam every 6 hours for 10-14 days.

Trial Locations (3)

15213

University of Pittsburgh Medical Center, Pittsburgh

90027

Children's Hospital Los Angeles, Los Angeles

06102

Hartford Hospital, Hartford

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Q2 Solutions

INDUSTRY

collaborator

Connecticut Children's Medical Center

OTHER

collaborator

St. Christopher's Hospital for Children

OTHER

collaborator

University of Texas Southwestern Medical Center

OTHER

collaborator

University of Pittsburgh Medical Center

OTHER

collaborator

Indiana University Health Methodist Hospital

OTHER

collaborator

James Whitcomb Riley Hospital for Children

OTHER

lead

Hartford Hospital

OTHER

NCT05561764 - Imipenem/Cilastatin/Relebactam Pharmacokinetics, Safety, and Outcomes in Adults and Adolescents With Cystic Fibrosis | Biotech Hunter | Biotech Hunter